N@N

CORCEPT THERAPEUTICS INCORPORATED (NASDAQ:CORT), Down By 8.90% ($0.29) From $3.260 After BUYINS.NET Report Predicted Weakness B

^{Published on 2011-08-05 05:28:20 - WOPRAI}
 

August 5, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, August 4th 2011 stating that CORCEPT THERAPEUTICS INCORPORATED (NASDAQ:CORT) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=cort&id=182876

At the time this story was written, CORCEPT THERAPEUTICS INCORPORATED (NASDAQ:CORT) is Down By 8.90% ($0.29) From $3.260 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

CORCEPT THERAPEUTICS INCORPORATED (NASDAQ:CORT) - Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. The company focuses on the development of drugs for disorders that are associated irregular levels of the steroid hormone called cortisol. Its lead product includes CORLUX, a glucocorticoid receptor II (GR-II) antagonist, which is in Phase III clinical trials for the treatment of Cushing's Syndrome and for psychotic depression. The company is also developing next-generation selective GR-II receptor antagonists for the treatment of various psychiatric and metabolic disorders. In addition, Corcept Therapeutics is developing CORT 108297, a lead compound from its selective GR-II antagonists for the prevention of weight gain induced by antipsychotic medication, which is in Phase I clinical trial. It has a patent license from Stanford University for the use of GR-II antagonists, as well as has agreements with ICON Clinical Research, LP; and MedAvante, Inc. The company was founded in 1998 and is headquartered in Menlo Park, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. CORCEPT THERAPEUTICS INCORPORATED (NASDAQ:CORT) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net